Health economic evaluation of rivaroxaban in the treatment of patients with chronic coronary artery disease or peripheral artery disease

AIMS: In the COMPASS trial, rivaroxaban 2.5 mg twice daily (bid) plus acetylsalicylic acid (ASA) 100 mg once daily (od) performed better than ASA 100 mg od alone in reducing the rate of cardiovascular disease, stroke, or myocardial infarction (MI) in patients with coronary artery disease (CAD) and p...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cardiovasc Res
Autors principals: Cowie, Martin R, Lamy, André, Levy, Pierre, Mealing, Stuart, Millier, Aurélie, Mernagh, Paul, Cristeau, Olivier, Bowrin, Kevin, Briere, Jean-Baptiste
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2020
Matèries:
Review Series from the Naples 2019 Joint Meeting of the ESC Working Groups on Myocardial Function and Cellular Biology of the Heart
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7449563/
https://ncbi.nlm.nih.gov/pubmed/31807773
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/cvr/cvz278
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars